Skip to content
777 Sourcing.

Capability

antisense oligonucleotide therapy development

Suppliers
1
Countries
1

1 antisense oligonucleotide therapy development supplier. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

DOLINNOV

MONTPELLIER

Dolinnov is a biotech company developing Precision Pump Modulators (PPMs), a novel class of non-opioid medicines for chronic pain. It is the first company worldwide to develop a lipid antisense oligonucleotide (L-ASO) therapy targeting FXYD2, a regulator of neuronal excitability in the DRG, to treat neuropathic and inflammatory chronic pain, including pain associated with rare diseases.

drug discoverypreclinical research

Compiled from public sources

Related capabilities

Other processes offered by the shops that list antisense oligonucleotide therapy development.

Browse all capabilities